on NEOVACS (EPA:ALNEV)
Fundraising by Neovacs
On December 17, 2024, Néovacs announced that it had raised €0.25 million through the issuance of OCEANE-BSA, subscribed by European High Growth Opportunities Securitization Fund. This fundraising will finance the Kinoïde® research program on allergies and will strengthen investment capacities in promising projects in biotechnology and medical devices.
The issuance of these financial instruments has already raised €26.4 million previously, with a consequent creation of more than 24 billion shares. The shareholders' stake is therefore significantly diluted, going from 1% to potentially 0.54% after this latest drawdown.
The risks associated with these dilutive financing operations are notified in the 2021 Annual Financial Report. Neovacs indicates that these fundraisings are crucial to ensure its liquidity, but warns that this could exert downward pressure on the share price.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NEOVACS news